The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,752,018 in first-year total cost, median $627,573.
Most frequent study sections
- Radiation Therapeutics and Biology Study Section[RTB]7
- Special Emphasis Panel[ZRG1 CTH-R (56)]4
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- JOHNS HOPKINS UNIVERSITY2
- RESEARCH INST NATIONWIDE CHILDREN'S HOSP1
- UNIVERSITY OF CALIFORNIA LOS ANGELES1
- UNIVERSITY OF NEBRASKA MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Selective treatment of acute myeloid leukemia with radioimmunotherapies targeting the active conformation of integrin beta-21R01CA297845-01A1 | FLAVELL, ROBERT RICHARDWIITA, ARUN P. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $678,101 | RTB |
| 2025 | Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer1R01CA297601-01 | BARCELLOS-HOFF, MARY HELENSEO, YOUNGHOVANBROCKLIN, HENRY F. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $676,567 | RTB |
| 2025 | Shark Radiotherapy for the Treatment of Triple-Negative Breast Cancer1R01CA295576-01A1 | LEBEAU, AARON MATTHEW | UNIVERSITY OF WISCONSIN-MADISON, WI | $630,171 | RTB |
| 2025 | In Vivo 3-D Multi-Isotope Autoradiography of Radiopharmaceutical Therapy1R01CA297470-01 | DU, YONGLI, QUANZHENGMENG, LING-JIAN | JOHNS HOPKINS UNIVERSITY, MD | $581,723 | RTB |
| 2025 | Targeting glutamine metabolism to enhance the efficacy of radiopharmaceutical therapy1R01CA295705-01 | BHUJWALLA, ZAVER M.RAY, SANGEETA | JOHNS HOPKINS UNIVERSITY, MD | $545,078 | RTB |
| 2024 | Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors1R01CA291827-01 | ZEPEDA-OROZCO, DIANA | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $627,573 | RTB |
| 2024 | Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer1R01CA290859-01 | GARRISON, JERED CJAIN, MANEESH | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $621,119 | RTB |
| 2023 | Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer1R01CA278882-01 | PRYMA, DANIEL A. | UNIVERSITY OF PENNSYLVANIA, PA | $678,844 | ZRG1 |
| 2023 | Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy1R01CA279203-01 | FLAVELL, ROBERT RICHARDSEO, YOUNGHOSRIRAM, RENUKA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $664,250 | ZRG1 |
| 2023 | Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC1R01CA279094-01 | CZERNIN, JOHANNESMONA, CHRISTINE ERADU, CAIUS GABRIEL | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $528,393 | ZRG1 |
| 2023 | Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation1R01CA279119-01 | SAWAKUCHI, GABRIEL OLIVEIRA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $520,199 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.